Key result
Each one-unit increase in time-weighted average hemoglobin was associated with a decreased risk of 1-year all-cause mortality (HR 0.714) in patients with acute myocardial infarction-related cardiogenic shock.
Why the study?
Anemia is implicated in prognosis across ischemic heart diseases, but the association between time-weighted average hemoglobin and all-cause mortality in acute myocardial infarction-related cardiogenic shock was unclear.
Does lower time-weighted average hemoglobin increase the risk of all-cause mortality in patients with acute myocardial infarction-related cardiogenic shock?
Cohort (n=765)
No
Does lower time-weighted average hemoglobin increase the risk of all-cause mortality in patients with acute myocardial infarction-related cardiogenic shock?
Hazard Ratio: 0.714 (95% CI 0.562–0.907)
Absolute Event Rate: 60% vs 46.7%
p-value: p=0.021
Lower time-weighted average hemoglobin during hospitalization is independently associated with increased long-term all-cause mortality in patients with acute myocardial infarction-related cardiogenic shock.
Low TWA-Hb identifies higher-risk AMI-CS patients; leaves open whether hemoglobin optimization improves survival.
Background and aims Anemia has been implicated in prognosis across ischemic heart diseases. This study aimed to investigate the association between time-weighted average hemoglobin (TWA-Hb) and all-cause mortality in patients with acute myocardial infarction-related cardiogenic shock (AMI-CS). Methods and results We conducted a retrospective analysis of 765 patients diagnosed with AMI-CS using data from the MIMIC-IV database (2008–2019). Kaplan–Meier survival analysis demonstrated that lower TWA-Hb levels were associated with higher cumulative mortality rates at 28 days, 90 days, 6 months, and 1 year (log-rank P = 0.002, 0.006, 0.048, and 0.005, respectively). Landmark analyses further revealed a sustained increase in mortality risk associated with lower TWA-Hb during the 28-day to 1-year follow-up period. Multivariable Cox regression analysis identified low TWA-Hb as an independent predictor of mortality risk at 90 days ( P = 0.026), 6 months ( P = 0.023), and 1 year ( P = 0.021). Each one-unit increase in TWA-Hb was associated with a 0.93-, 0.76- and 0.71-fold decrease in the risk of 90-day, 6-month, and 1-year mortality, correspondingly. Subgroup analyses stratified by age, BMI, and comorbidities consistently supported these findings (all P < 0.05). Conclusion Low TWA-Hb is associated with long-term mortality in patients with AMI-CS. These findings imply that the application of this indicator in clinical practice could improve long-term risk stratification.
No takes yet. Share an insight, caveat, or question.
Liu et al. (2025) conducted a cohort in Acute myocardial infarction-related cardiogenic shock (n=765). Time-weighted average hemoglobin (TWA-Hb) vs. Higher TWA-Hb levels was evaluated on All-cause mortality at 1 year (HR 0.714, 95% CI 0.562-0.907, p=0.021). Each one-unit increase in time-weighted average hemoglobin was associated with a decreased risk of 1-year all-cause mortality (HR 0.714) in patients with acute myocardial infarction-related cardiogenic shock.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: